Fundraising FoxOrbus Therapeutics
Aptos, US · Founded 2012 · 6 known investors
Find your way into Orbus Therapeutics
Sign up to see every warm intro you have to Orbus Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Orbus Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Orbus Therapeutics is a clinical-stage biopharmaceutical company developing eflornithine (DFMO), an oral ODC inhibitor, as a cancer therapy. Its lead candidate targets recurrent grade 3 IDH-mutant astrocytoma and other cancers with ODC overexpression.
Founders & leadership
Orbus Therapeutics was founded in 2012 by Jason Levin.
Board
Investors · 6
How we know: H.I.G. HealthBridge Partners's portfolio page · Not right? Tell us
How we know: funding news · press coverage · the VCSheet dataset · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$46.5M disclosed across 3 rounds · 2015–2020
▶$10MraisedAug 2020 · 1 investors · BiotechnologyRule 506(b)
- Kurt von EmsterDirector
- Robert M. MyersExecutive Officer, Director
- Elisha (Terry) GouldDirector
- Ernest MarioDirector
- Patrick EnrightDirector
- Jason D. LevinExecutive Officer, Director
- Michael WassermanDirector
- Offering amount
- $27M
- Amount sold
- $10M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.5MraisedMar 2019 · 16 investors · BiotechnologyRule 506(b)
- Michael WassermanDirector
- Patrick EnrightDirector
- Jason D. LevinExecutive Officer, Director
- Ernest MarioDirector
- Elisha (Terry) GouldDirector
- Robert M. MyersExecutive Officer, Director
- Offering amount
- $39.5M
- Amount sold
- $18.5M
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18MraisedAug 2015 · 15 investors · BiotechnologyRule 506(b)
- Jason D. LevinExecutive Officer, Director
- Ernest MarioDirector
- Michael WassermanDirector
- Patrick EnrightDirector
- Elisha (Terry) GouldDirector
- Robert M. MyersExecutive Officer, Director
- Offering amount
- $32.5M
- Amount sold
- $18M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Orbus Therapeutics do?
- Orbus Therapeutics is a clinical-stage biopharmaceutical company developing eflornithine (DFMO), an oral ODC inhibitor, as a cancer therapy. Its lead candidate targets recurrent grade 3 IDH-mutant astrocytoma and other cancers with ODC overexpression.
- Who founded Orbus Therapeutics?
- Orbus Therapeutics was founded by Jason Levin in 2012.
- Who are Orbus Therapeutics's investors?
- Orbus Therapeutics's investors include H.I.G. Capital, H.I.G. HealthBridge Partners, Longitude Capital, Abingworth, Adams Street Partners, Agent Capital.
- How much funding has Orbus Therapeutics raised?
- Orbus Therapeutics has disclosed $46.5M raised across 3 rounds.
- Where is Orbus Therapeutics headquartered?
- Orbus Therapeutics is headquartered in Aptos, US.